63 related articles for article (PubMed ID: 5069876)
1. Clinical effects of combined vasopressin--corticosteroid therapy in patients with recurrent grade 3 astrocytomas.
Bernard-Weil E; Landau-Ferey J; Ancri D; Pertuiset B
Neurochirurgia (Stuttg); 1972 Jul; 15(4):127-34. PubMed ID: 5069876
[No Abstract] [Full Text] [Related]
2. [Effects of a vasopressin-corticoid association in patients having an astrocytoma or cerebral metastasis. Evolutive study using complementary methods].
Bernard-Weil E; David M; Pertuiset B; Hirsch JF; Fischgold H
Neurochirurgia (Stuttg); 1968 Sep; 11(5):189-99. PubMed ID: 4306909
[No Abstract] [Full Text] [Related]
3. Phase II evaluation of infusional etoposide and cisplatin in patients with recurrent astrocytoma.
Buckner JC; Brown LD; Cascino TL; Gerstner JB; Krook JE; Westberg MW; Wiesenfeld M; O'Fallon JR; Scheithauer B
J Neurooncol; 1990 Dec; 9(3):249-54. PubMed ID: 2086739
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the addition to corticoids of a growth factor (vasopressin) in the palliative therapy of malignant brain tumours.
Bernard-Weil E
Neurol Res; 1991 Jun; 13(2):94-102. PubMed ID: 1682847
[TBL] [Abstract][Full Text] [Related]
5. [The inhibitory effects of corticosteroid on the proliferation of tumor cells derived from human astrocytoma-gliobastoma--with special reference to combined vasopressin--corticosteroid therapy (author's transl)].
Kajikawa H
No Shinkei Geka; 1975 Jan; 3(1):51-6. PubMed ID: 1238914
[TBL] [Abstract][Full Text] [Related]
6. [Undifferentiated astrocytoma of the cerebrum. A review of current therapeutic possibilities].
Seiler RW
Schriftenr Neurol; 1982; 22():1-114. PubMed ID: 7100830
[No Abstract] [Full Text] [Related]
7. Phase I-II evaluation of intra-arterial diaziquone for recurrent malignant astrocytomas.
Greenberg HS; Ensminger WD; Layton PB; Gebarski S; Meyer M; Chaffee B; Bender JF; Grillo-Lopez AJ
Cancer Treat Rep; 1986 Mar; 70(3):353-7. PubMed ID: 3006913
[TBL] [Abstract][Full Text] [Related]
8. [Chemotherapy protocol "8 drugs in 1 day" in patients with recurrent malignant glioma].
Jeremić B; Grujicić D; Matović M
Srp Arh Celok Lek; 1994; 122(3-4):73-5. PubMed ID: 17972813
[TBL] [Abstract][Full Text] [Related]
9. [Hormonal (vasopressin-corticoid) treatment of 16 cases of inoperable cerebral tumors with little or no malignant potential].
Bernard-Weil E; Metzger J; Pertuiset B
Sem Hop; 1973 May; 49(23):1687-97. PubMed ID: 4356221
[No Abstract] [Full Text] [Related]
10. Regression of grade III astrocytoma during the treatment of CML with imatinib mesylate.
Jayawardena S; Sooriabalan D; Indulkar S; Kim HH; Matin A; Maini A
Am J Ther; 2006; 13(5):458-9. PubMed ID: 16988542
[TBL] [Abstract][Full Text] [Related]
11. [Chemotherapy in brain tumors].
van den Bent MJ; Schellens JH; Sillevis Smitt PA; Vecht CJ
Ned Tijdschr Geneeskd; 1996 Mar; 140(13):702-6. PubMed ID: 8668248
[No Abstract] [Full Text] [Related]
12. Treatment of recurrent malignant supratentorial astrocytomas with carboplatin and etoposide combined with recombinant mutant human tumor necrosis factor-alpha.
Yamamoto M; Oshiro S; Tsugu H; Hirakawa K; Ikeda K; Soma G; Fukushima T
Anticancer Res; 2002; 22(4):2447-53. PubMed ID: 12174942
[TBL] [Abstract][Full Text] [Related]
13. [Individualized therapy and outcomes of microsurgery, radiotherapy, and chemotherapy for astrocytoma].
Zhou WN; Chen ZP; You C; Mu YG; Sai K; Zhang JY; Zhang XH; Cheng JJ; Xu HC
Ai Zheng; 2004 Nov; 23(11 Suppl):1555-60. PubMed ID: 15566679
[TBL] [Abstract][Full Text] [Related]
14. [Medical management of malignant gliomas].
Béhin A; Delattre JY
Cancer Radiother; 2000 Nov; 4 Suppl 1():67s-83s. PubMed ID: 11194966
[TBL] [Abstract][Full Text] [Related]
15. Mathematical model for hormonal therapy (vasopressin, corticoids) in cerebral collapse and malignant tumors of the brain (36 cases).
Bernard-Weil E; Pertuiset B
Neurol Res; 1983; 5(1):19-35. PubMed ID: 6140654
[TBL] [Abstract][Full Text] [Related]
16. Correlation of the expression of nuclear factor-kappa B, tumor necrosis factor receptor type 1 (TNFR 1) and c-Myc with the clinical course in the treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2).
Yamamoto M; Fukushima T; Hayashi S; Ikeda K; Tsugu H; Kimura H; Soma G; Tomonaga M
Anticancer Res; 2000; 20(1C):611-8. PubMed ID: 10769704
[TBL] [Abstract][Full Text] [Related]
17. BCNU-DBD (Dibromodulcitol) chemotherapy of recurrent supratentorial anaplastic astrocytomas and glioblastomas.
Vitanovics D; Sipos L; Afra D
Neoplasma; 2002; 49(5):342-5. PubMed ID: 12458335
[TBL] [Abstract][Full Text] [Related]
18. Vasopressin plus corticosteroids: the shock duo!
Annane D
Crit Care Med; 2009 Mar; 37(3):1126-7. PubMed ID: 19237927
[No Abstract] [Full Text] [Related]
19. Chemotherapy in recurrent noncystic low-grade astrocytomas of the cerebrum in children.
Sumer T; Freeman AI; Cohen M; Bremer AM; Thomas PR; Sinks LF
J Surg Oncol; 1978; 10(1):45-54. PubMed ID: 628217
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of supratentorial glioma with intracarotid cisplatin and intravenous carmustine].
Rebollo J; Martín-Algarra S; Bilbao I; Zubieta JL; Calvo FA; de Castro P; Pastor MA; Viteri C; Martínez Lage JM
Neurologia; 1990; 5(7):228-32. PubMed ID: 1963067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
